⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 15, 2025

Supplementary Figure S7 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition

Qi Ye Bohan Ma Lei Li Zixi Wang Mingming Lu Jialu Kang Yuzeshi Lei Shan Xu Ke Wang Yanlin Jian Yizeng Fan Bin Wang Jing Liu Yang Gao Jian Ma Lei Li

View Full Paper

Ask AI

Bookmark

Share

Key Points

BPD sensitizes HR proficient prostate cancer cells to PARP inhibitors, enhancing treatment efficacy.
The observed synthetic lethality highlights important interactions between BRCA2 and PARP inhibition.
Supplementary figure S7 illustrates the impact of the PROTAC degrader on prostate cancer cell sensitivity.
The findings indicate potential new therapeutic strategies for metastatic castration-resistant prostate cancer.

Implication

Supplementary figure shows that PROTAC degrader sensitizes HR proficient prostate cancer to PARP inhibitors, suggesting new therapeutic approaches.

Abstract

Supplementary Fig. S7. BPD sensitizes HR proficient prostate cancer cells to synthetic lethality by PARP inhibitors. Related to Fig. 5.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ye et al. (2025) studied this question.

synapsesocial.com/papers/68d46ccf31b076d99fa68fb8 https://doi.org/10.1158/0008-5472.30125740

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S5 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition2025
2Supplementary Figure S3 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition2025
3Supplementary Figure S4 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition2025
4Supplementary Figure S6 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition2025
5Supplementary Figure S1 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition2025